ABT vs TMDX
ABT: A diversified global health care leader focused on diagnostic, medical device, nutritional, and pharmaceutical solutions. TMDX: TransMedics commercializes the only FDA-approved portable warm perfusion platform for multi-organ transplantation, replacing cold storage to dramatically increase donor organ utilization and post-transplant outcomes.
Side-by-side fundamentals
| Metric | ABT | TMDX | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $104.49 | $74.28 | |
| Market cap as of 2026-07-29 | $182.0B | $2.6B | |
| P/E as of 2026-07-29 | 33.63 | 17.54 | TMDX lower |
| PEG as of 2026-07-29 | 2.66 | 0.08 | TMDX lower |
| Net margin as of 2026-07-29 | +11.7% | +27.0% | TMDX higher |
| Gross margin as of 2026-07-29 | +56.8% | +59.1% | TMDX higher |
| Operating margin as of 2026-07-29 | +15.8% | +14.8% | ABT higher |
| ROE as of 2026-07-29 | +12.2% | +41.9% | TMDX higher |
| ROA as of 2026-07-29 | +6.9% | +15.8% | TMDX higher |
| Debt / equity as of 2026-07-29 | 0.65 | 1.73 | ABT lower |
| Revenue growth (YoY) as of 2026-07-29 | +8.1% | +30.2% | TMDX higher |
| Revenue CAGR (3y) SEC XBRL | +0.5% | +86.4% | TMDX higher |
| Dividend yield as of 2026-07-29 | +2.3% | n/a | |
| Dividend streak (yrs) SEC XBRL | 4 | 0 | ABT higher |
| Beta as of 2026-07-29 | 0.57 | 1.92 | |
| 1-year return as of 2026-07-27 close | -17.4% | -31.3% | ABT higher |
Fundamentals: Finnhub, as of 2026-07-29. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.